--- title: "U.S. stock night market opening fluctuations: Genenta Science S.P.A. rose 18.45% in the night market; Virgin Galactic rose 11.49% in the night market" type: "News" locale: "en" url: "https://longbridge.com/en/news/288189526.md" description: "Genenta Science S.P.A. rose 18.45% in after-hours trading; Virgin Galactic rose 11.49% in after-hours trading; Lisata Therapeutics rose 32.31% in after-hours trading; Scinai Immunotherapeutics rose 24.22% in after-hours trading; Replimune rose 22.90% in after-hours trading" datetime: "2026-06-01T00:16:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288189526.md) - [en](https://longbridge.com/en/news/288189526.md) - [zh-HK](https://longbridge.com/zh-HK/news/288189526.md) --- # U.S. stock night market opening fluctuations: Genenta Science S.P.A. rose 18.45% in the night market; Virgin Galactic rose 11.49% in the night market **U.S. Stock Night Market Opening Movements** Genenta Science S.P.A. rose 18.45% in the night market. Based on recent key news: 1. On May 29, Genenta Science S.P.A. released its latest announcement through the EDGAR system of the U.S. Securities and Exchange Commission, detailing the company's latest R&D progress and financial status. This announcement triggered a positive market reaction, driving the stock price up. 2. Recently, the biotechnology industry has performed strongly overall, with increased investor interest in innovative drugs and therapies, further boosting Genenta Science S.P.A.'s stock price. 3. Analysts hold an optimistic view on Genenta Science S.P.A.'s future prospects, raising ratings and believing the company is expected to achieve significant growth in the coming years. The biotechnology industry has recently performed strongly, with increased investor interest. Virgin Galactic rose 11.49% in the night market. Based on recent key news: 1. On May 29, Virgin Galactic announced that a federal court preliminarily approved a settlement plan to resolve two long-standing shareholder derivative lawsuits. This news drove the stock price up, reflecting investor optimism about reduced legal risks for the company. Source: Benzinga 2. On May 28, Virgin Galactic announced that the settlement plan includes a payment of $2.75 million from the insurance company, half of which will be retained by the company. This move is expected to eliminate related claims and further enhance market confidence. Source: Reuters 3. On May 29, analysts pointed out that despite the stock price increase, there is a lack of value and growth indicators, and investors should remain cautious. This view may limit further increases in the stock price. Source: Benzinga Industry competition is intensifying, and investors need to be cautious. **Top Gainers in the U.S. Stock Night Market** Lisata Therapeutics rose 32.31% in the night market. Based on recent key news: 1. On May 29, Lisata Therapeutics announced a modification of its merger offer to $4 per share plus CVR, leading to a significant rise in the stock price. According to SEC filings, the company adjusted the merger terms, and the market reacted positively, pushing the stock price up by 32.31%. Source: Reuters 2. On May 29, Lisata Therapeutics released relevant information through the EDGAR system, further confirming the changes to the merger terms. This information was provided by the company and enhanced investor confidence. Source: Public Technologies Recent volatility in U.S. stocks has increased, and risks need to be monitored. Scinai Immunotherapeutics rose 24.22% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation Replimune rose 22.90% in after-hours trading. Based on recent key news: 1. On May 29, Replimune announced an agreement with the FDA to resubmit its approval application for the melanoma drug RP1. The drug had previously been rejected twice, and the FDA indicated it would prioritize this application, boosting investor confidence and causing the stock price to surge 74% in pre-market trading. Source: Reuters 2. On May 30, the company announced that RP1 combined with Opdivo achieved a median overall survival of 32.9 months in melanoma patients who had failed PD-1 treatment, further enhancing market confidence in the efficacy of its drug. Source: Reuters 3. On May 31, Replimune presented the first human data for RP2 in advanced solid tumors at the American Society of Clinical Oncology annual meeting, further increasing market recognition of its R&D capabilities. Source: GlobeNewswire The biotechnology sector has been volatile recently, and policy changes should be monitored ### Related Stocks - [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md) - [SPCE.US](https://longbridge.com/en/quote/SPCE.US.md) - [LSTA.US](https://longbridge.com/en/quote/LSTA.US.md) - [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md) - [REPL.US](https://longbridge.com/en/quote/REPL.US.md) ## Related News & Research - [Virgin Galactic Shareholders Approve Expanded Long-Term Incentive Plan](https://longbridge.com/en/news/289834122.md) - [Virgin Galactic (SPCE) Stock Valuation After Glide Tests Resume And Debt For Equity Swap](https://longbridge.com/en/news/289803588.md) - [Hecla Mining (HL) Stock Valuation After Strong 1 Year Return And Recent Weakness](https://longbridge.com/en/news/289685931.md) - [Isabella Bank to Acquire Grand River Commerce in Cash-and-Stock Deal: $18.3M Cash, 839k Shares](https://longbridge.com/en/news/289830975.md) - [If You Invested $100 In Deutsche Bank Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/289811744.md)